The global smart inhalers market was valued at $118 million in 2020, and is estimated to reach $1,113.57 million by 2030, growing at a CAGR of 25.1% from 2021 to 2030.
Smart inhalers are devices used for delivering a variety of medication through inhalation and can be connected to devices such as smartphones or any digital device. The drugs used in the inhalers include, anti-cholinergic, glucocorticoids, insulin, and beta-agonists for the treatment and prevention of respiratory diseases, such as asthma and chronic obstructive pulmonary diseases (COPD). Smart inhalers have sensors that send feeds back, reminders and monitors an individual’s health regularly. It also notifies about high pollution areas as well high pollen threat.
Smart inhalers have proved to increase the adherence rate in patients suffering from asthma and COPD. Moreover, smart inhalers also help to monitor the technique used for inhaling the medicine in an effective manner as compared to normal inhalers. Smart Inhalers are of two types, namely metered dose inhalers and dry powder inhalers.
This market is majorly driven by increase in population suffering from asthma and COPD. Increase in air pollution directly increases asthma and other respiratory cases, which in turn, boosts the demand for smart monitoring devices. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, causing 3.23 million deaths in 2019 and more than 80% of these deaths occurred in low and middle income countries. Thus, such large mortality and unmet medical demands can be reduced by increased initiatives and utilization of smart inhalers and is an opportunity for the investors to invest in such countries.
For instance, in July 2020, Novartis International AG, one of the leading players received European Commission’s (EC) approval for Enerzair Breezhaler, the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the European Union. It was developed in collaboration with Propeller Health’s app and sensor custom-built for the Breezhaler device. Thus, launch of such products and collaborations among the key market players further boost the market growth.
Market players have invested in various developing smart inhalers products that aid in monitoring asthma and COPD, wherein, the data acquired by the sensors of these smart inhalers is shared with the patient and healthcare professionals to track their inhaler usage. The data monitored is then shared using the Bluetooth technology to their mobile apps through an online platform and subsequently, electronic health records (EHR) or electronic medical records (EMR) are maintained.
Smart inhalers are expected to increase the adherence rate of patients to traditional inhalers. Unintended non-adherence arises when patients misunderstand instructions and forget or have physical problems such as poor coordination or eyesight, thus leading to limited ability to take their medicines. Smart inhalers, such as the Adherium’s Hailie solution is a cloud-based platform, which captures medication use data from Bluetooth enabled sensors that wraps around patient inhalers and provides real-time feedback to patients via the Hailie app and to their physicians via the Hailie portal. Increase in non-adherence is known to be a source of disease to patients as well as financial burden to payers and prescribers. Thus, increase in adherence to smart inhalers is expected to improve the treatment of asthma and COPD patients.
However, as smart inhalers are wirelessly connected and keep a record of the patient’s data, the risk of data leakage and misuse of data increases significantly. As smart inhaler is a new device, its acceptance among patients as well as physicians is considerably low and is thus, expected to restrain the growth of the market. Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities for market growth during the forecast period.
The smart inhalers market is segmented into product, indication, distribution channel, and region. On the basis of product, the market is segmented into inhalers and nebulizers. The inhalers are further bifurcated dry powdered inhalers (DPIs) and metered dose inhalers (MDI's) . On the basis of indication, the market is segmented into asthma and COPD. On the basis of distribution channel, the market is bifurcated in to hospital pharmacies and retail pharmacies.
Region wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, Middle East, and Africa (LAMEA).
The major players profiled in the report are Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, Llc., GlaxoSmithKline Plc, Novartis AG, OPKO Health Inc., Philip Morris International Inc. (Vectura Group Plc), ResMed Inc. (Propeller Health) and Teva Pharmaceutical Industries Ltd.
Smart inhalers are devices used for delivering a variety of medication through inhalation and can be connected to devices such as smartphones or any digital device. The drugs used in the inhalers include, anti-cholinergic, glucocorticoids, insulin, and beta-agonists for the treatment and prevention of respiratory diseases, such as asthma and chronic obstructive pulmonary diseases (COPD). Smart inhalers have sensors that send feeds back, reminders and monitors an individual’s health regularly. It also notifies about high pollution areas as well high pollen threat.
Smart inhalers have proved to increase the adherence rate in patients suffering from asthma and COPD. Moreover, smart inhalers also help to monitor the technique used for inhaling the medicine in an effective manner as compared to normal inhalers. Smart Inhalers are of two types, namely metered dose inhalers and dry powder inhalers.
This market is majorly driven by increase in population suffering from asthma and COPD. Increase in air pollution directly increases asthma and other respiratory cases, which in turn, boosts the demand for smart monitoring devices. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, causing 3.23 million deaths in 2019 and more than 80% of these deaths occurred in low and middle income countries. Thus, such large mortality and unmet medical demands can be reduced by increased initiatives and utilization of smart inhalers and is an opportunity for the investors to invest in such countries.
For instance, in July 2020, Novartis International AG, one of the leading players received European Commission’s (EC) approval for Enerzair Breezhaler, the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the European Union. It was developed in collaboration with Propeller Health’s app and sensor custom-built for the Breezhaler device. Thus, launch of such products and collaborations among the key market players further boost the market growth.
Market players have invested in various developing smart inhalers products that aid in monitoring asthma and COPD, wherein, the data acquired by the sensors of these smart inhalers is shared with the patient and healthcare professionals to track their inhaler usage. The data monitored is then shared using the Bluetooth technology to their mobile apps through an online platform and subsequently, electronic health records (EHR) or electronic medical records (EMR) are maintained.
Smart inhalers are expected to increase the adherence rate of patients to traditional inhalers. Unintended non-adherence arises when patients misunderstand instructions and forget or have physical problems such as poor coordination or eyesight, thus leading to limited ability to take their medicines. Smart inhalers, such as the Adherium’s Hailie solution is a cloud-based platform, which captures medication use data from Bluetooth enabled sensors that wraps around patient inhalers and provides real-time feedback to patients via the Hailie app and to their physicians via the Hailie portal. Increase in non-adherence is known to be a source of disease to patients as well as financial burden to payers and prescribers. Thus, increase in adherence to smart inhalers is expected to improve the treatment of asthma and COPD patients.
However, as smart inhalers are wirelessly connected and keep a record of the patient’s data, the risk of data leakage and misuse of data increases significantly. As smart inhaler is a new device, its acceptance among patients as well as physicians is considerably low and is thus, expected to restrain the growth of the market. Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities for market growth during the forecast period.
The smart inhalers market is segmented into product, indication, distribution channel, and region. On the basis of product, the market is segmented into inhalers and nebulizers. The inhalers are further bifurcated dry powdered inhalers (DPIs) and metered dose inhalers (MDI's) . On the basis of indication, the market is segmented into asthma and COPD. On the basis of distribution channel, the market is bifurcated in to hospital pharmacies and retail pharmacies.
Region wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, Middle East, and Africa (LAMEA).
The major players profiled in the report are Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, Llc., GlaxoSmithKline Plc, Novartis AG, OPKO Health Inc., Philip Morris International Inc. (Vectura Group Plc), ResMed Inc. (Propeller Health) and Teva Pharmaceutical Industries Ltd.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global smart inhalers market to identify the prevailing opportunities
- This study presents the competitive landscape of the global market to predict the competitive environment across geographies
- Comprehensive analysis of factors that drive and restrict the market growth is provided
- Region- & country-wise analysis is provided to understand the market trends and dynamics
KEY MARKET SEGMENTS
By Product
- Inhalers
- Dry Powdered Inhalers (DPIs)
- Metered Dose Inhalers (MDI's)
- Nebulizers
By Indication
- Asthma
- COPD
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
By Region
- North America
- US
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Russia
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- UAE
- Turkey
- Saudi Arabia
- Rest of LAMEA
KEY MARKET PLAYERS
- Adherium Limited
- Aptar Group Inc (Cohero Health Inc)
- AstraZeneca, Inc
- Cognita Labs, LLC
- GlaxoSmithKline Plc
- Novartis AG
- OPKO Health Inc
- Philip Morris International Inc (Vectura Group Plc)
- Resmed Inc (Propeller Health)
- Teva Pharmaceutical Industries Ltd
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Landscape
Chapter 4: Smart Inhalers Market, by Product
Chapter 5: Smart Inhalers Market, by Indication
Chapter 6: Smart Inhalers Market, by End-user
Chapter 7: Smart Inhalers Market, by Region
Chapter 8: Company Profiles
List of Tables
List of Figures
Executive Summary
According to a new report titled, Smart Inhalers Market by Product, Indication, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021–2030, the global smart inhalers market was valued at $118 million in 2020, and is projected to reach $1,113.57 million by 2030, registering a CAGR of 25.1% from 2021 to 2030.Smart inhalers are devices used for delivering several inhaled medications, such as anticholinergics, glucocorticoids, and beta antagonists for treating respiratory diseases. Smart inhalers contain sensors that are connected to inhaler devices, which allows maintaining the record of inhaler, increasing the adherence, and monitoring of the patient.
A smart inhaler is an inhaler that is improved by technology. These medical devices make use of technology to aid in the collection of health data. This information can assist the doctor to note more personalised treatment decisions. Some smart inhalers have sensors that can detect if a person is in a high-pollution or high-pollen area, while others can send helpful reminders and tell if one needs to check the inhaler technique. They're all designed to automatically track how frequently one uses its inhaler, so one does not have to keep track of it.
The growth of the smart inhalers market is majorly driven due to rise in prevalence of asthma and COPD. Moreover, increase in air pollution and rise in indoor air pollutant further increase the chances of having respiratory disorders. Better treatment option, ease of use, and technological advancements coupled with increase in adherence rate of patients to smart inhalers are major factors that drive the smart inhalers market.
Furthermore, according to the U.S. Centers for Disease Control and Prevention, in 2019, around 25.1 million people were suffering from asthma, including 5.1 million children. Thus, such high number of patients is expected to boost the market significantly.
Moreover, in September 2021, Adherium Limited announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its first, next generation Hailie sensor with physiological measures for monitoring asthma and (COPD) medication use. It is designed for use with AstraZeneca’s Symbicort aerosol inhaler, to enable physicians and providers to enhance patient care and clinical workflow by capturing clinical data and supporting patient management and treatment. Thus, such collaborations and product approval strategies among the key players are expected to propel the market growth significantly.
However, risk of misuse of data and and breach of data privacy, high cost of asthma & COPD treatment, and low awareness about smart inhalers are expected to impede the market growth. Conversely, high market potential in the untapped emerging economies, rise in various product launches, partnerships, collaborations among the government & key players, and development of pipeline products are expected to provide many opportunities for market growth during the forecast period.
By product type, the market is segmented into inhalers and nebulizers. The inhalers segment generated maximum revenue in 2020, accounting $112.86 million. The nebulizers segment is expected to witness highest CAGR of 27.3% during the forecast period.
By indication, the market is segmented into asthma and COPD. The asthma segment generated maximum revenue in 2020, accounting $63.55 million. The COPD segment is expected to witness highest CAGR of 25.4% during the forecast period.
On the basis of distribution channel, the market is segmented into hospital pharmacies and retail pharmacies. The retail pharmacies segment generated maximum revenue in 2020, accounting $69.21 million and is expected to witness highest CAGR of 25.4% during the forecast period.
North America exhibited the global smart inhalers market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to better healthcare infrastructure and facilities, prevalence in the number of patient suffering from asthma and COPD, adoption of technologically advanced treatments, presence of key players, and rise healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to its high geriatric population base, increase in disposable incomes, surge in healthcare expenditure, and various developmental activities.
Key Findings Of The Study
- By product, inhaler segment was the highest contributor to the market in 2020
- By indication, asthma segment was the highest contributor to the market in 2020
- On the basis of distribution channel, retail pharmacies segment was the highest contributor to the market in 2020
- Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
Companies Mentioned
- Adherium Limited
- Aptar Group Inc. (Cohero Health Inc.)
- AstraZeneca, Inc.
- Cognita Labs, Llc.
- GlaxoSmithKline Plc
- Novartis AG
- OPKO Health Inc.
- Philip Morris International Inc. (Vectura Group Plc)
- ResMed Inc. (Propeller Health)
- Teva Pharmaceutical Industries Ltd.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 173 |
| Published | February 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 118 million |
| Forecasted Market Value ( USD | $ 1113.57 million |
| Compound Annual Growth Rate | 25.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
